PATENT CLAIM ANALYSIS

Application Number: 16322112
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-05
Patent Classification: ["514", "473000"]

Abstract:
The present invention discloses a novel phosphodiesterase 4 (PDE4) inhibitor ZL-n-91 for applications in preparing drugs for treating proliferation and metastasis of prostate cancer. The animal experiments and cytological experiments in mice showed that the PDE4 inhibitor ZL-n-91 of the present invention can significantly inhibit the proliferation and metastasis of prostate cancer cells, indicating that the PDE4 inhibitor ZL-n-91 is expected to be an important target for treating proliferation and metastasis of prostate cancer. It will lay a foundation for preparing drugs against proliferation and metastasis of prostate cancer, presenting good prospect for development and application.

Claim (Index 7):
The method according to  claim 5 , which inhibits prostate cancer metastasis.

Metadata:
- Claim Count in Document: 9.0
- Percentile: 99.0
- Lexical Diversity: 1.83929
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14367926', '14478175', '15403965', '14007683', '10324993']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7545788062427213
- 35 USC 102 Novelty (BERT): 0.4975218094480982
- Combined Prediction Score: 0.728873106563259
- Mean Citation Score: 175.865998
- Max Citation Score: 181.12997
- Similarity Product: 113.32369377021789

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test